Medindia

X

NexBio Initiates Phase II Trial of DAS181 (Fludase(R)*) for Treatment of Influenza, Including Pandemic Influenza A(H1N1)

Friday, January 8, 2010 Respiratory Disease News J E 4
Advertisement

Contact:

David Wurtman, M.D., M.B.A.

VP, Corporate Development

10665 Sorrento Valley Road

San Diego, CA  92121

Phone: (858) 452-2631

dwurtman@nexbio.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New England Biolabs Introduces a Tunable T7 Expres...
S
Amira Pharmaceuticals Achieves Development Milesto...